VOR — Vor Biopharma Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1817229 ·
Last close
$18.18
Market Cap
$1.12B
52W High
$26.00
52W Low
$6.50
ADV30
772,625
Next earnings
2026-10-30

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -58,444,000 -86,727,000 496,312,000 78,977,000 633,485,000
Jun 2026 0 — -47,853,000 -62,810,000 481,053,000 107,855,000 681,250,000
Mar 2026 0 — -35,160,000 -219,585,000 506,746,000 169,873,000 657,170,000
Dec 2025 0 — -35,960,000 1,722,858,000 464,126,000 396,486,000 628,438,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-140,087,000
Investing CF
$-348,989,000
Financing CF
$404,112,000
CapEx
$-726,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-379.14
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,435,367,000
Inventory
—
Receivables
—
ST Investments
$358,274,000
EBIT TTM
$-147,080,000
Pretax Income TTM
$627,779,000
Interest Exp TTM
—
Analysts
8

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -371,642,000 -695,981,000 464,126,000 628,438,000 -164,312,000 -142,713,000
Dec 2024 0 -121,185,000 -116,914,000 142,891,000 46,227,000 96,664,000 -99,660,000
Dec 2023 0 -126,036,000 -117,863,000 198,126,000 47,402,000 150,724,000 -100,292,000
Dec 2022 0 -93,418,000 -92,094,000 299,366,000 48,759,000 250,607,000 -85,144,000

TTM Snapshot

Revenues TTM
$12,804,000
NetIncome TTM
$627,779,000
OpCashFlow TTM
—
Assets (Latest)
$481,053,000
Forward EPS
$-3.67

Max Pain — expiry 2027-05-21

max pain strike: $20.00 · spot: $17.83 · call oi: 3,389 · put oi: 422
Expected Move to 2027-05-21: ±$12.95 (72.63%) — implied range $4.88 – $30.78 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
INBX Inhibrx Biosciences, Inc. $1.09B $74.18 —
IMTX Immatics N.V. $957.50M $6.29 —
TSHA Taysha Gene Therapies, Inc. $1.30B $4.00 —
NVAX NOVAVAX INC $1.31B $7.96 —
ODTX Odyssey Therapeutics, Inc. $931.07M $19.37 —

News headlines (Yahoo Finance, 1h cache)

Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
2026-11-13 02:15 · Yahoo
Vor Biopharma Adds RC298 to RemeGen License Deal
2026-11-12 15:44 · Yahoo
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
2026-11-10 13:00 · Yahoo
Vor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year Slide
2026-11-06 21:11 · Yahoo
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:15 · Yahoo
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
2026-10-08 15:17 · Yahoo
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
2026-10-04 16:05 · Yahoo
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
2026-09-08 11:00 · Yahoo
Vor Bio To Participate in Upcoming September Conferences
2026-09-01 12:00 · Yahoo
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
2026-11-12 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.